138 related articles for article (PubMed ID: 33556973)
1. [Unusual cause of hypercalcemia in pregnancy].
Mehl L; Schrader J; Winterberg T; Daniels T; Gross A; Weidner U; Clauditz TS; Lock G
Z Gastroenterol; 2021 Feb; 59(2):143-148. PubMed ID: 33556973
[TBL] [Abstract][Full Text] [Related]
2. Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia.
Kanakis G; Kaltsas G; Granberg D; Grimelius L; Papaioannou D; Tsolakis AV; Öberg K
J Clin Endocrinol Metab; 2012 Apr; 97(4):E627-31. PubMed ID: 22319031
[TBL] [Abstract][Full Text] [Related]
3. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
Behdadnia A; Jeddi M
J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
[TBL] [Abstract][Full Text] [Related]
4. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide.
van de Loosdrecht AA; van Bodegraven AA; Sepers JM; Sindram JW
Neth J Med; 1998 Sep; 53(3):118-23. PubMed ID: 9803143
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases].
Miura M; Shibahara H; Morita K; Matsui K; Itoh Y; Shimizu J; Takeuchi A; Narita M; Nishimura D; Katada N
Nihon Shokakibyo Gakkai Zasshi; 2015 Mar; 112(3):537-46. PubMed ID: 25759229
[TBL] [Abstract][Full Text] [Related]
8. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide.
Barhoum M; Hutchins L; Fonseca VA
Am J Med Sci; 1999 Sep; 318(3):203-5. PubMed ID: 10487414
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.
Iliuta IA; Beauregard JM; Couture F; Douville P; Mac-Way F
Clin Nucl Med; 2015 Sep; 40(9):e448-50. PubMed ID: 26053724
[TBL] [Abstract][Full Text] [Related]
10. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
Symington M; Davies L; Kaltsas G; Weickert MO
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
[TBL] [Abstract][Full Text] [Related]
11. Case report of multimodality treatment for metastatic parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour.
Rossi RE; Naik K; Navalkissoor S; Imber C; O'Beirne J; Toumpanakis C; Caplin ME
Tumori; 2014; 100(4):153e-6e. PubMed ID: 25296608
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemic crisis in third trimenon: evaluating the optimal treatment strategy.
Refardt J; Farina P; Hoesli I; Meier C
Gynecol Endocrinol; 2018 Oct; 34(10):833-836. PubMed ID: 29658374
[TBL] [Abstract][Full Text] [Related]
13. Severe hypercalcaemia from secretion of parathyroid hormone-related peptide.
Barakat MT; Ashrafian H; Todd JF; Meeran K; Williams GR
Lancet Oncol; 2004 Oct; 5(10):633-5. PubMed ID: 15465467
[No Abstract] [Full Text] [Related]
14. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
Müssig K; Petersenn S; Wehrmann M; Horger M; Vierling P; Häring HU; Gallwitz B
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):719-23. PubMed ID: 17625444
[TBL] [Abstract][Full Text] [Related]
15. Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour.
Mantzoros CS; Suva LJ; Moses AC; Spark R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):373-5. PubMed ID: 9156050
[TBL] [Abstract][Full Text] [Related]
16. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors. Report of six cases.
Milanesi A; Yu R; Wolin EM
Pancreatology; 2013; 13(3):324-6. PubMed ID: 23719609
[TBL] [Abstract][Full Text] [Related]
17. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
[TBL] [Abstract][Full Text] [Related]
18. A case of watery diarrhea, hypokalemia and hypercalcemia associated with nonulcerogenic islet cell tumor of the pancreas.
Hirose S; Kobayashi K; Kajikawa K; Sawabu N
Am J Gastroenterol; 1975 Nov; 64(5):382-91. PubMed ID: 174423
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia and pancreatic endocrine neoplasia with elevated PTH-rP: report of two new cases and subject review.
Matsen SL; Yeo CJ; Hruban RH; Choti MA
J Gastrointest Surg; 2005 Feb; 9(2):270-9. PubMed ID: 15694824
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
